By Devika Patel
Knoxville, Tenn., July 17 – Amicus Therapeutics, Inc. negotiated a $400 million six-year senior secured term loan facility with Hayfin Capital Management on July 17, according to a press release and an 8-K filed with the Securities and Exchange Commission. Hayfin Services LLP was the agent.
The loan bears interest at Libor plus 650 basis points.
The full amount of this facility is available and will be fully drawn at close.
Proceeds will be used to refinance existing debt and for other general corporate and product development purposes.
Amicus is a Cranbury, N.J.-based biotechnology company focused on orphan drugs for rare diseases.
| Issuer: | Amicus Therapeutics, Inc.
|
| Issue: | Senior secured term loan facility
|
| Amount: | $400 million
|
| Maturity: | Six years
|
| Coupon: | Libor plus 650 bps
|
| Agent: | Hayfin Services LLP
|
| Investor: | Hayfin Capital Management
|
| Pricing date: | July 17
|
| Settlement date: | Aug. 4
|
| Distribution: | Private placement
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
